Myelodysplastic Syndromes

FDA Approves Inqovi for Patients with High-Risk Myelodysplastic Syndromes
FDA Approvals, News & UpdatesMyelodysplastic Syndromes
On July 7, 2020, the FDA approved Inqovi (decitabine plus cedazuridine; from Astex Pharmaceuticals and Taiho Oncology) tablets for the treatment of adults with intermediate- or high-risk myelodysplastic syndromes, or MDS, including patients with chronic myelomonocytic leukemia. Inqovi is an orally administered fixed-dose combination of the hypomethylating agent decitabine plus the cytidine deaminase inhibitor cedazuridine.
Understanding Myelodysplastic Syndromes
From Your NavigatorMyelodysplastic Syndromes
Myelodysplastic syndromes are a group of cancers that affect immature blood cells in the bone marrow. Two oncology navigators explain the risk factors and current treatment options available for patients diagnosed with this type of malignancy.

Results 1 - 2 of 2

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.